TELOMIR PHARMACEUTICALS INC (TELO) Stock Price, Quote, News and Overview
NASDAQ:TELO - Nasdaq - US87975F1049 - Common Stock - Currency: USD
TELO Quote, Performance and Key Statistics
2.15
+0.14 (+6.97%)
The current stock price of TELO is 2.15 USD. In the past month the price decreased by -14.68%. In the past year, price decreased by -61.81%.
TELO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.95 | 729.65B | ||
| JNJ | JOHNSON & JOHNSON | 15.43 | 373.01B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.73 | 331.61B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.2 | 233.10B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.56 | 225.96B | ||
| MRK | MERCK & CO. INC. | 10.14 | 198.30B | ||
| PFE | PFIZER INC | 7.27 | 132.75B | ||
| SNY | SANOFI-ADR | 11.34 | 122.83B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.6 | 98.52B | ||
| GSK | GSK PLC-SPON ADR | 9.24 | 83.58B | ||
| ZTS | ZOETIS INC | 28.27 | 75.76B | ||
| HLN | HALEON PLC-ADR | 22.14 | 49.84B |
Related stock screener links
About TELO
Company Profile
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The company is headquartered in Tampa, Florida and currently employs 0 full-time employees. The company went IPO on 2024-02-09. The firm is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. The company is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. The company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Company Info
TELOMIR PHARMACEUTICALS INC
900 West Platt Street, Suite 200
Tampa FLORIDA US
Employees: 0
Phone: 18138642562
TELOMIR PHARMACEUTICALS INC / TELO FAQ
What is the stock price of TELOMIR PHARMACEUTICALS INC today?
The current stock price of TELO is 2.15 USD. The price increased by 6.97% in the last trading session.
What is the ticker symbol for TELOMIR PHARMACEUTICALS INC stock?
The exchange symbol of TELOMIR PHARMACEUTICALS INC is TELO and it is listed on the Nasdaq exchange.
On which exchange is TELO stock listed?
TELO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TELOMIR PHARMACEUTICALS INC stock?
null analysts have analysed TELO and the average price target is 15.56 USD. This implies a price increase of 623.49% is expected in the next year compared to the current price of 2.15. Check the TELOMIR PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TELOMIR PHARMACEUTICALS INC worth?
TELOMIR PHARMACEUTICALS INC (TELO) has a market capitalization of 63.98M USD. This makes TELO a Micro Cap stock.
How many employees does TELOMIR PHARMACEUTICALS INC have?
TELOMIR PHARMACEUTICALS INC (TELO) currently has 0 employees.
What are the support and resistance levels for TELOMIR PHARMACEUTICALS INC (TELO) stock?
TELOMIR PHARMACEUTICALS INC (TELO) has a resistance level at 2.16. Check the full technical report for a detailed analysis of TELO support and resistance levels.
Should I buy TELOMIR PHARMACEUTICALS INC (TELO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TELO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TELO, evaluating the profitability, health, valuation and growth aspects
- TELOMIR PHARMACEUTICALS INC (TELO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TELOMIR PHARMACEUTICALS INC (TELO) Sales and EPS estimates to see what analysts future expectations are.
- TELOMIR PHARMACEUTICALS INC (TELO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TELOMIR PHARMACEUTICALS INC (TELO) Insider and Institutional Ownership to learn about the owners and their transactions.
- TELOMIR PHARMACEUTICALS INC (TELO) Stock Chart to make your own analysis
- TELOMIR PHARMACEUTICALS INC (TELO) Latest news and press-releases to stay up to date.
Does TELOMIR PHARMACEUTICALS INC (TELO) stock pay dividends?
TELO does not pay a dividend.
When does TELOMIR PHARMACEUTICALS INC (TELO) report earnings?
TELOMIR PHARMACEUTICALS INC (TELO) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of TELOMIR PHARMACEUTICALS INC (TELO)?
TELOMIR PHARMACEUTICALS INC (TELO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.63).
What is the Short Interest ratio of TELOMIR PHARMACEUTICALS INC (TELO) stock?
The outstanding short interest for TELOMIR PHARMACEUTICALS INC (TELO) is 11.09% of its float. Check the ownership tab for more information on the TELO short interest.
TELO Technical Analysis
TELO Financial Highlights
Over the last trailing twelve months TELO reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 8.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3809.55% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |